Molecular and cellular pathobiology HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1416-1428

  Cuadros, Thaïs ^a   Trilla, Enric ^c   Sarro, Eduard ^a   Vila, Maya R ^a   Vilardell, Jordi ^d   De Torres, Ines ^c   Salcedo, Mayte ^c   Lopez Hellin, Joan ^a   Sanchez, Alex ^b   Cajal, Santiago Ramon Y ^c   Itarte, Emilio ^d   Morote, Juan ^c   Meseguer, Anna ^a,e,f  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Statistics and Bioinformatics Unit (UEB) Vall d'Hebron Institute of Research   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Group de Mutagènesi Departament de Genètica i de Microbiologia Facultat de Biociències   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f Section of Nephrology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; KIDNEY INJURY MOLECULE 1; PROTEIN HIF 1A; STAT3 PROTEIN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; HAVCR1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IL6 PROTEIN, HUMAN; MEMBRANE PROTEIN; STAT3 PROTEIN, HUMAN; VIRUS RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GENE EXPRESSION REGULATION; GENE SILENCING; HIF 1A GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IL 6 GENE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAT3 GENE; TUMOR GENE; TUMOR VASCULARIZATION; UPREGULATION; CELL LINE; DISEASE COURSE; GENETICS; HEK293 CELL LINE; KIDNEY TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL LINE; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERLEUKIN-6; KIDNEY NEOPLASMS; MEMBRANE GLYCOPROTEINS; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84896538821     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1671     Document Type: Article

References (32)

1. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 2002;167:57-60.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. Cancer J Clin 2008;58:71-96.
3. Chow W-H, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7:245-57.
4. Escudier B, Kataja V ESMO Guidelines Working Group. Renal cell carcinoma:ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:137-9.
5. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011;108: 1556-63.
6. Vila MR, Kaplan GG, Feigelstock D, Nadal M, Morote J, Porta R, et al. Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. Kidney Int 2004;65:1761-73.
7. Kaplan G, Totsuka A, Thompson P, Akatsuka T, Moritsugu Y, Feinstone SM. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J 1996; 15:4282-96.
8. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. Kidney injury molecule-1 (HKIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998;273:4135-42.
9. McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2001;2:1109-16.
10. Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, Bonventre JV. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 2002;277:39739-48.
11. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (HKIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62:237-44.
12. Han WK, Alinani A, Wu CL, Michaelson D, Loda M, McGovern FJ, et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol 2005;16:1126-34.
13. Lin F, Zhang PL, Yang XJ, Shi J, Blasick T, Han WK, et al. Human Kidney Injury Molecule-1 (HKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol 2007;31:371-81.
14. Cuadros T, Trilla E, Vila MR, de Torres I, Vilardell J, Messaoud NB, et al. hHAVRc-1/KIM-1 represents a susceptibility gene for development of clear cell renal cell carcinoma (ccRCC) and shedding of hHAVRc-1/ KIM-1 ectodomain a predictive biomarker of tumor progression. Eur J Cancer 2013;49:2034-47.
15. Gogusev J, Augusti M, Chretien Y, Droz D. Interleukin-6 and TNF a production in human renal cell carcinoma. Kidney Int 1993;44:585-92.
16. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989;250:607-10.
17. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-22.
18. Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 1991;83:1668-72.
19. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
20. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-Type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297-314.
21. Heinrich PC, Behrmann I, Haan S, Hermanns HM, M̈uller-Newen G, Schaper F. Principles of interleukin (IL)-6-Type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
22. Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, YangYM, et al. STAT-3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 2005;19:1296-8.
23. Horiguchi A, Oya M, Marumo K, Murai M. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769-P. Kidney Int 2002;61:926-38.
24. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 2002;168:762-5.
25. Guo C, Yang G, Khun K, Kong X, Levy D, Lee P, et al. Activation of STAT-3 in renal tumors. Am J Transl Res 2009;1:283-90.
26. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641-52.
27. Dorevic G, Matusan-Ilijas K, Babarovic E, Hadzisejdic I, Grahovac M, Grahovac B, et al. Hypoxia inducible factor-1a correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2009;28:40.
28. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499:43-9.
29. Lim AI, Chan LY, Lai KN, Tang SC, Chow CW, Lam MF, et al. Distinct role of matrix metalloproteinase-3 in kidney injury molecule-1 shedding by kidney proximal tubular epithelial cells. Int J Biochem Cell Biol 2012;44:1040-50.
30. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. STAT-3 mediates myeloid cell dependent tumor angiogenesis in mice. J Clin Invest 2008;118:3367-77.
31. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGFb-driven program in stromal cells for metastasis initiation. Cancer Cell 2012;22:571-84.
32. Yamanishi Y, Kitaura J, Izawa K, Kaitani A, Komeno Y, Nakamura M, et al. TIM1 is an endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury. J Exp Med 2010;207:1501-11.